Dr Pete

FDA approves treatment for leading cause of vision loss… Is there a time between 7:00am – 12:30pm ET on November 18th that works for you here? BREAKING MEDICAL NEWS -- INTERVIEW OPPORTUNITY FOR MONDAY, NOVEMBER 18, 2019 FDA APPROVES NEW TREATMENT FOR WET AMD, A LEADING CAUSE OF VISION LOSS It's estimated by next year, 1.5 to 1.75 million people in the US will be living with WET AGE-RELATED MACULAR DEGENERATION (wet AMD). It's a leading cause of vision loss and a rapidly growing public health concern.[1-3] It can start with your vision becoming distorted. It’s harder to see objects clearly.[4] If allowed to progress, it could lead to complete loss of central vision, leaving you unable to read, drive or even recognize familiar faces.[5] Novartis has just received FDA approval of a new treatment that has the potential to help people affected by wet AMD maintain their vision. Dr. Peter Kaiser, Director of the Cole Center for Ocular Research and Evaluation and Professor of Ophthalmology at the Cleveland Clinic, knows what patients and their families go through with this disease. He is available to answer your questions and to discuss: How wet AMD robs people of precious sight and impacts millions of lives Ways to detect wet AMD New treatment option for wet AMD Resources to help people cope with this condition Challenges of caring for someone with AMD When you book, we will provide you with supplemental b-roll, guest bio & suggested questions. Interview courtesy of Novartis Pharmaceuticals Corporation. INDICATIONS AND USAGE BEOVU® (brolucizumab-dbll) injection is indicated for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD). IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS BEOVU is contraindicated in patients with ocular or periocular infections, active intraocular inflammation or known hypersensitivity to brolucizumab or any of the excipients in BEOVU. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, erythema, or severe intraocular inflammation. Please see additional Important Safety Information below and the full Prescribing Information. WARNINGS AND PRECAUTIONS Endophthalmitis and Retinal Detachments Intravitreal injections, including those with BEOVU, have been associated with endophthalmitis and retinal detachments. Proper aseptic injection techniques must always be used when administering BEOVU. Patients should be instructed to report any symptoms suggestive of endophthalmit